27,070 Shares in Boston Scientific Corporation $BSX Bought by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 27,070 shares of the medical equipment provider’s stock, valued at approximately $2,908,000. Boston Scientific makes up 1.0% of Lecap Asset Management Ltd.’s portfolio, making the stock its 4th biggest position.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. ASR Vermogensbeheer N.V. lifted its position in shares of Boston Scientific by 0.4% in the second quarter. ASR Vermogensbeheer N.V. now owns 454,047 shares of the medical equipment provider’s stock valued at $48,768,000 after acquiring an additional 1,770 shares in the last quarter. Consolidated Planning Corp lifted its position in shares of Boston Scientific by 2.3% in the second quarter. Consolidated Planning Corp now owns 50,313 shares of the medical equipment provider’s stock valued at $5,404,000 after acquiring an additional 1,133 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of Boston Scientific by 31.6% in the second quarter. Robeco Institutional Asset Management B.V. now owns 3,145,777 shares of the medical equipment provider’s stock valued at $337,888,000 after acquiring an additional 756,199 shares in the last quarter. BSW Wealth Partners lifted its position in shares of Boston Scientific by 2.2% in the second quarter. BSW Wealth Partners now owns 8,667 shares of the medical equipment provider’s stock valued at $931,000 after acquiring an additional 188 shares in the last quarter. Finally, Woodward Diversified Capital LLC acquired a new position in Boston Scientific in the second quarter valued at $205,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on BSX. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. UBS Group upped their target price on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and upped their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Leerink Partners upped their target price on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $120.67.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $95.78 on Thursday. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The business has a 50-day moving average of $103.30 and a 200-day moving average of $102.08. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $141.91 billion, a price-to-earnings ratio of 57.01, a PEG ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,214 shares of company stock valued at $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.